Welcome to our dedicated page for CRISPR Therapeutics SEC filings (Ticker: CRSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CRISPR Therapeutics AG filings document operating results, pipeline disclosures and capital-structure matters for a Swiss biopharmaceutical company developing gene-based medicines. Form 8-K reports furnish quarterly and annual financial results, business highlights for CASGEVY and investigational programs, clinical and regulatory updates across cardiovascular, autoimmune, immuno-oncology and regenerative medicine, and material-event disclosures.
The filing record also includes proxy materials covering shareholder voting and executive compensation, shelf-registration and prospectus-supplement disclosures for common-share offerings, and material definitive agreements for convertible senior notes due 2031. These filings describe common shares, equity financing mechanics, debt terms, governance matters and business disclosures tied to the company’s CRISPR/Cas9, LNP, CAR-T and siRNA platforms.
CRISPR Therapeutics AG has a significant shareholder group led by Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd, which together report beneficial ownership of 5,449,161 shares of Common Stock, representing 5.6% of the class as of June 30, 2026.
Orbis Investment Management Ltd, organized in Bermuda, holds 5,433,344 shares with sole voting and sole dispositive power. Allan Gray Australia Pty Ltd, organized in Australia, holds 15,817 shares with sole voting and sole dispositive power. Neither reports any shared voting or dispositive power. Other persons have rights to receive dividends and sale proceeds on the securities each firm beneficially owns, and each reporting person disclaims beneficial ownership of shares held by the other.
CRISPR Therapeutics AG Chief Financial Officer Prasad Raju reported a bona fide gift of 750 Common Shares on 2026-08-07. The transfer is classified as a disposition, and following the gift he reports 14,815 Common Shares held directly.
CRISPR Therapeutics reported Q2 2026 total revenue of approximately $10.2 million, mainly from collaboration revenue, and a net loss of about $91.2 million (basic and diluted loss per share $0.94). For the first half of 2026, revenue was roughly $11.6 million with a net loss of about $214.1 million.
As of June 30 2026, the company held $2.65 billion in total assets, including substantial marketable securities and cash, and reported total liabilities of $904.2 million. Long-term debt consisted primarily of $600 million of Convertible Senior Notes due 2031, with a net carrying amount of $586.2 million.
The business centers on CRISPR-based therapeutics across hemoglobinopathies, in vivo liver editing, siRNA programs, CAR‑T and regenerative medicine. Key programs include CASGEVY, an approved CRISPR/Cas9 gene-edited therapy for sickle cell disease and transfusion‑dependent beta thalassemia, and pipeline candidates such as CTX310, CTX611 and next‑generation CAR‑T asset zugocabtagene geleucel.
CRISPR Therapeutics reported second quarter 2026 results, highlighted by rapid commercial progress for CASGEVY. CASGEVY generated $76 million in revenue, up 78% sequentially and 151% year over year, and is approved in 39 countries. The FDA expanded its label to children 2 years and older with sickle cell disease or transfusion‑dependent beta thalassemia, potentially enabling treatment for about 5,500 additional patients, while Vertex secured reimbursement in Germany for eligible patients 12 and older.
Beyond CASGEVY, the company advanced a broad gene‑editing portfolio, including Phase 1 trials for CTX340 in refractory hypertension and CTX460 in alpha‑1 antitrypsin deficiency, ongoing CTX310 liver programs, siRNA candidate CTX611 in Phase 2, and allogeneic CAR‑T zugo‑cel in multiple autoimmune and oncology indications. Cash, cash equivalents and marketable securities totaled $2,364.4 million as of June 30, 2026, supported by $585.4 million of convertible senior note proceeds in March. Second‑quarter R&D expense was $67.2 million, collaboration expense $40.3 million, and net loss narrowed to $91.2 million from $208.5 million a year earlier.
BlackRock, Inc. filed an amended ownership report showing a significant stake in CRISPR Therapeutics AG common stock. BlackRock reported beneficial ownership of 7,987,262 shares, representing 8.3% of the class.
BlackRock reported sole voting power over 7,841,979 shares and sole dispositive power over 7,987,262 shares, with no shared voting or dispositive power. The filing notes that various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of CRISPR Therapeutics AG’s outstanding common shares.
CRISPR Therapeutics AG director George Simeon received a grant of stock options for 13,000 common shares. The options carry an exercise price of $51.84 per share and expire on June 5, 2036. This is a compensation-related award, not an open-market trade.
According to the vesting terms, the options vest in 12 equal monthly installments, subject to his continued service. The first installment vests on June 30, 2026, and the final installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting.
CRISPR Therapeutics AG director Ali Behbahani received a new stock option grant covering 13,000 common shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036. They were awarded as compensation rather than bought on the open market.
According to the vesting terms, the options vest in 12 equal monthly installments, with the first installment on June 30, 2026. The final installment vests on the earlier of the one-year anniversary of the grant date or the date of the company’s 2027 annual meeting.
CRISPR Therapeutics AG director Maria Fardis received a grant of stock options, giving her the right to buy 13,000 common shares at an exercise price of $51.84 per share. These options were awarded as compensation, not through open-market buying or selling.
According to the vesting terms, the 13,000 options will vest in 12 equal monthly installments, with the first installment vesting on June 30, 2026. The final installment will vest on the earlier of the one-year anniversary of the grant date or the date of the company’s 2027 Annual Meeting, assuming she continues to provide service to the company or its subsidiaries.
CRISPR Therapeutics AG reported that director Harold Edward Fleming received a grant of stock options covering 13,000 common shares. The options have an exercise price of 51.84 per share and expire on June 5, 2036. Subject to continued service, they vest in 12 equal monthly installments, beginning with the first installment on June 30, 2026 and the last on the earlier of the one-year anniversary of the grant date or the 2027 annual meeting.
CRISPR Therapeutics AG director John Greene received a grant of stock options covering 13,000 common shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036.
According to the vesting terms, the award vests in 12 equal monthly installments, subject to continued service. The first installment vests on June 30, 2026, and the last installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting.